Key factors
symMYL
exchUS
MCap8.586B
Beta1.465
PE Ratio30.72
EPS0.516
Div date2007-06-27
Yesterday
symMYL
exchUS
close0.079
50 Day MA16.42
200 Day MA16.11
Target Price 21.75
Market Cap Mln8586.21
Share statistics
Shares Outstanding541.54M
Shares Float538.05M
Percent Institutions90.49
PercentInsiders0.912
SharesShort47.14M
Short Ratio11.15
Shares Short Prior Month46.48M
Short Percent11.05
Revenue TTM 11.51B
Revenue Per Share TTM 22.28
Quarterly Revenue Growth YOY 0.400
Gross Profit TTM 4.551B
EBITDA3.512B
Diluted Eps TTM0.516
Quarterly Earnings Growth YOY-2.30
earning
Operating Margin TTM 0.157
PEGRatio 1.59
Trailing PE 30.72
EPS Estimate Current Quarter 1.16
EPS Estimate Current Year 4.58
EPS Estimate Next Quarter 1.33
EPS Estimate Next Year 4.68
Earnings Share 0.516
Dividend
Dividend Date0000-00-00
Last Split Date 2003-10-09
Last Split Factor3:2
business
Enterprise Value Ebitda 11.86
Enterprise Value Revenue2.799
Book Value /share 24.27
Price Book MRQ 1.635
Price Sales TTM 0.767
ProfitMargin 0.023
ReturnOnAssetsTTM 0.036
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryPharmaceuticals
Gic Sector Health Care
Gic Sub Industry Pharmaceuticals
Industry Drug Manufacturers - Specialty & Generic
SectorHealthcare
ISIN USN594651093
CIK 1623613
Code MYL
CUSIP 628530107
Employer Id Number 98-1189497
CountryISO US
Currency CodeUSD
Currency Name US Dollar
Exchange NASDAQ
Currency Symbol $
Type Common Stock
UpdatedAt 2021-01-17
is Delisted 1
Delisted Date 2020-11-19
Home Category Domestic
Fiscal Year End December
ForwardPE 3.776
Full Time Employees35000
IPODate 1987-12-18
International Domestic International Domestic
MostRecent Quarter2020-09-30
Contact
NameViatris Inc
AddressBuilding 4, Hatfield, United Kingdom, AL10 9UL
Country NameUSA
Phone44 1707 853 000
Web URLwww.mylan.com
Logo URL/img/logos/US/Myl.png
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.